Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00539760 · ClinicalTrials.gov registry record · Phase 1
A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00539760 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 45 participants.
The verdict
NCT00539760, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
GSK182771 is a domain antibody targeting the interleukin (IL)-1 receptor which is being developed for the treatment of rheumatoid arthritis. This study is being done in healthy volunteers to verify the safety and tolerability of GSK182771
Interventions
- DRUG Placebo
- DRUG GSK1827771
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2007-09-05 |
| Est. Completion | 2008-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00539760
The ClinicalTrials.gov registry entry for NCT00539760 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00539760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00539760 about?
NCT00539760 is a clinical study titled "A Phase I Rheumatoid Arthritis Study in Healthy Volunteers". GSK182771 is a domain antibody targeting the interleukin (IL)-1 receptor which is being developed for the treatment of rheumatoid arthritis. This study is being done in healthy volunteers to verify the safety and tolerability of GSK182771
What is the current status of trial NCT00539760?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2007-09-05. Estimated completion is 2008-04-05.
What interventions are being tested in trial NCT00539760?
The interventions under investigation include: Placebo (DRUG), GSK1827771 (DRUG).
Who is sponsoring clinical trial NCT00539760?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.